Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cintredekin besudotox

Next Previous
X
Search
Drug Profile

Cintredekin besudotox

Alternative Names: hIL13-PE38QQR; IL13-PE38; IL13-PE38QQR; Interleukin-13-PE38QQR immunotoxin; NK 408

Latest Information Update: 21 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer INSYS Therapeutics, Inc; National Institutes of Health (USA); Nippon Kayaku
  • Class Antineoplastics; Drug conjugates; Exotoxins; Immunotoxins; Interleukins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaplastic astrocytoma; Idiopathic pulmonary fibrosis; Glioblastoma; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adrenocortical carcinoma; Asthma; Glioma; Pulmonary fibrosis

Most Recent Events

  • 17 Nov 2014 Insys Therapeutics terminates a phase I/II trial in Adrenocortical carcinoma (metastatic disease, second-line therapy or greater) in USA (NCT01832974)
  • 01 Jul 2011 Insys Therapeutics completes a phase I trial in Malignant glioma (newly diagnosed) in USA (NCT00089427)
  • 31 Oct 2010 US FDA puts a hold on the IND application for cintredekin besudotox in Idiopathic pulmonary fibrosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top